A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma


The purpose of this study is to look at whether the investigational product, rocatinlimab, works, and how safe it is for moderate to severe asthma.


Currently recruiting participants: Yes

Eligible ages: 18 to 75

Inclusion criteria:

You might be eligible if:
1) 18 to 75 years of age
2) you have moderate to severe asthma.

Exclusion criteria:

You might not be eligible if:
1) you do not have moderate to severe asthma
2) you are under the age of 18
3) you are pregnant or breastfeeding.


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

If you would like to learn more about how you can get involved with this study, please contact our study coordinator, Madison, at 403-220-7827.

Principal investigator:

Richard Leigh

Clinical trial: